Valecobulin

Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA) . Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].

Product Specifications

CAS Number

[1188371-47-2]

Product Name Alternative

CKD-516

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Valecobulin.html

Purity

98.47

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(C)[C@H](N)C(NC1=NC(C2=CC=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C(N4N=CN=C4)=C2)=CS1)=O

Molecular Formula

C26H28N6O5S

Molecular Weight

536.60

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362-P403+P233-P405-P501

References & Citations

[1]Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. J Med Chem. 2010 Sep 9;53 (17) :6337-54.|[2]Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. Radiology. 2014 Aug;272 (2) :417-26.